Qure AI vs Viz.ai (2026)
The same underlying technology, detection on an image, pointed at different problems. Viz.ai detects and then mobilizes: its stroke product, ContaCT, received the 2018 De Novo that created the regulation for triage and notification, and Viz One gets the treating team moving, with randomized trial evidence of shorter door to groin times. Qure detects across chest X-ray, head CT and chest CT in more than 105 countries by its own count, with tuberculosis screening products and care platforms for health programs. Its US clearances are reading aids and triage devices, including qER for head CT and qXR-Detect, a concurrent reading aid for chest X-ray with a Predetermined Change Control Plan. For a US health system with an interventional stroke pathway, Viz.ai is built to shorten time to treatment. For a program reading large volumes of chest imaging with limited specialist capacity, Qure is built for that.
- Chest imaging at program scale, with tuberculosis screening evidence from independent studies in several countries and a 2025 systematic review.
- A cleared change plan for chest X-ray detection: qXR-Detect's Predetermined Change Control Plan sets out how the model can be updated and how users are told.
- A stated privacy position: its cloud path receives only images stripped of identifiers, and on premise installation keeps processing on the customer's own servers.
- A cleared portfolio built on the triage category its stroke product created, with more than 50 cleared algorithms reported across imaging, cardiac tracings and echocardiography.
- Evidence on care delivery: a post hoc analysis of a multicenter prospective randomized trial reported door to groin times 11 minutes shorter.
- The communication layer is the product: the finding reaches the treating team automatically on their phones, which is what converts a detection into faster treatment.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Qure AI and Viz.ai are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Qure.ai, founded in 2016 in Mumbai with a US entity in New York, sells radiology AI in more than 105 countries through more than 5,500 sites by its own count. Its products are qXR for chest X-ray (detection, reporting, lung nodules and tuberculosis screening), qER for head CT in stroke and trauma, qCT for chest CT nodules and lung cancer, qMSK for musculoskeletal X-ray, and heart failure detection.
Source: AI Health Index, September 2026
AI powered care coordination platform, Viz One, that pairs detection algorithms on imaging and ECG with automatic alerts and team messaging on clinicians' phones. It began in stroke: its large vessel occlusion product, ContaCT, received FDA's De Novo authorization in 2018 (DEN170073), which created the regulatory category for imaging triage and notification software.
Source: AI Health Index, September 2026
Questions buyers ask
How do Qure AI and Viz.ai work with the EHR?
For Qure AI, the qXR page promises zero integration effort and deployment on cloud or on premise, the company says its software works with new and old X-ray systems, and the qXR-Detect summary describes results returned to radiology software or the X-ray console; qXR-LN is cleared for use with any DICOM viewer or PACS.
With Viz.ai, the platform receives DICOM studies from scanners and PACS, and the De Novo summary describes the notification path to the mobile app with the images attached. The app is the working surface for neurologists, interventionalists and stroke teams across hospital networks. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
How are Qure AI and Viz.ai priced and sold?
In Qure AI's case, the portfolio makes the gap matter. Qure sells chest X-ray, head and chest CT and musculoskeletal products under ten US clearances, plus tuberculosis care cascades and the Aira care delivery platform, and nothing says whether indications are licensed singly, bundled by modality or sold as a platform.
For Viz.ai, the website sets out how the product is sold: Viz One is an enterprise platform with therapeutic suites (neuro, vascular, cardio, pulmonary, trauma, radiology, oncology) and pilot programs, and the route in is a contact form. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
How do Qure AI and Viz.ai handle patient data?
Qure's Security and Regulatory page says data is de-identified before it leaves a covered entity's premises for cloud processing, and that on-premise installations may process identifiable images only on servers the customer owns and operates.
The customer's contract sets how long Viz.ai keeps customer data. Usage data (which studies and alerts a clinician opened, response times) is de-identified to the HIPAA standard at 45 CFR 164.514 before it is used to improve services, build new products or conduct research. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
Which settings and specialties do Qure AI and Viz.ai cover?
Qure covers chest X-ray, head and chest CT and musculoskeletal X-ray, sold to hospitals, imaging centers, teleradiology services, immigration screening and public health programs in more than 105 countries.
With Viz.ai, the oncology, respiratory, neurology and osteoporosis offers are sold as pilot programs. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
The consequence of a missed finding differs between these deployments. In triage and notification a radiologist still reads every study. Qure markets sorting out unremarkable chest X-rays and does not say who reads the studies set aside, a use outside its US clearances, so ask before switching it on. Viz.ai sells some modules as pilot programs, and a pilot is not a clearance.
Prevalence compounds this: the same sensitivity and specificity produce very different positive predictive values in a screening population than in an acute one. Neither publishes pricing.